Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2000

View Archived Issues

U.S. and U.K. authorities sanction Glaxo Wellcome/SmithKline Beecham merger

Repligen licenses two patent applications from UCSD related to uses of uridine

Vivus granted third PDE inhibitor patent

Collaboration announced by Maxygen and Integrated Genomics

Questcor arranges Asian marketing agreement for metoclopramide nasal spray

Pierre Fabre describes bacterial cell wall protein with potential as cancer immunotherapy

Exclusive rights to nucleoside analogue acquired from SRI by Gilead

Commencement of phase I trial of IL-1 Trap for rheumatoid arthritis announced by Regeneron

Trial with nasal calcitonin concludes successfully

Positive allosteric modulators of GABA-A receptor designed and evaluated by European group

Nucleoside analogue MIV-210 enters phase I for HBV treatment

Celltech completes acquisition of Cistron

Immunomedics licenses humanized antibody for NHL to Amgen

Aldose reductase inhibitor developed in Japan submitted for regulatory review

Kyowa Hakko discusses work leading to development of therapeutically active 5-HT4 agonists

SD/01 is equally effective and safe as once-daily filgrastim over multiple cycles of chemotherapy

Dolastatin 10 has no significant efficacy in advanced breast cancer

Results from ongoing phase II trial of 9-NC in metastatic breast cancer reported in San Antonio

Faslodex highlighted at Breast Cancer Symposium as a novel approach to postmenopausal breast cancer

GABA analogues reported to modulate substance P

New use claimed by Sanofi-Synthelabo for succinic acid derivatives

Tetralone and thienylcyclohexanone derivatives selectively bind to GABA-A alpha5 subunit

Protein farnesyltransferase inhibitors useful for cancer therapy patented by BMS

New 4-arylpiperidine derivatives for the treatment of pruritus

Pfizer presents new mu-selective opioid receptor ligands and use thereof

Combined 5-HT1A/5-HT2/D2 receptor agonists designed at FAES

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...